245 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28089699	63	Investigation of piperazine benzamides as humanß	Merck
28523097	37	Similarity- and Substructure-Based Development ofß	Philipps University Marburg
2859372	7	Conjugates of catecholamines. 5. Synthesis and beta-adrenergic activity of N-(aminoalkyl)norepinephrine derivatives.	TBA
27876250	60	Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH	Jagiellonian University Medical College
27692547	7	Synthesis and activity of newly designed aroxyalkyl or aroxyethoxyethyl derivatives of piperazine on the cardiovascular and the central nervous systems.	Jagiellonian University Medical College
27132867	154	Structure-guided development of dualß2 adrenergic/dopamine D2 receptor agonists.	Friedrich-Alexander University
26988801	55	Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.	Jagiellonian University Medical College
26709102	142	Discovery of Vibegron: A Potent and Selectiveß3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.	Merck Research Laboratories
26125514	40	Discovery of Novel Indazole Derivatives as Highly Potent and Selective Humanß3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.	Asahi Kasei Pharma
25065493	92	The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-actingß2-adrenoceptor agonist.	Novartis Institutes For Biomedical Research
24835980	98	Discovery of TD-4306, a long-actingß2-agonist for the treatment of asthma and COPD.	Theravance
24813741	110	Multivalent design of long-actingß(2)-adrenoceptor agonists incorporating biarylamines.	Theravance
16640337	47	Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.	Glaxosmithkline
24100078	59	Click chemistry based synthesis of dopamine D4 selective receptor ligands for the selection of potential PET tracers.	Friedrich-Alexander University
23614528	121	Synthesis and in vitro and in vivo characterization of highlyß1-selectiveß-adrenoceptor partial agonists.	University of Nottingham
23614494	2	Structure-based fragment screening is demonstrated to be a practical lead discovery method for a representative G-protein-coupled receptor.	Pfizer
23517028	2	Biophysical fragment screening of theß1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design.	Heptares Therapeutics
21870877	119	Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for humanß-adrenoceptors.	University of Nottingham
17507221	58	Identification and SAR of potent and selective non-peptide obeline somatostatin sst1 receptor antagonists.	Novartis Institutes For Biomedical Research
16759089	5	Role of Tyr(356(7.43)) and Ser(190(4.57)) in antagonist binding in the rat beta1-adrenergic receptor.	The University of Melbourne
11806709	63	Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres.	Glaxosmithkline
1346651	29	Synthesis of halogenated trimetoquinol derivatives and evaluation of their beta-agonist and thromboxane A2 (TXA2) antagonist activities.	Ohio State University
22932315	28	An investigation into the structure-activity relationships associated with the systematic modification of theß(2)-adrenoceptor agonist indacaterol.	Novartis Institutes For Biomedical Research
22079756	219	From libraries to candidate: the discovery of new ultra long-acting dibasicß2-adrenoceptor agonists.	Astrazeneca
22178551	46	A multivalent approach to the discovery of long-actingß(2)-adrenoceptor agonists for the treatment of asthma and COPD.	Theravance
21925889	48	The discovery of long-acting saligeninß2 adrenergic receptor agonists incorporating a urea group.	Glaxosmithkline
21696967	51	The discovery of long-acting saligeninß2 adrenergic receptor agonists incorporating hydantoin or uracil rings.	Glaxosmithkline
21723724	91	Design-driven LO: the discovery of new ultra long acting dibasicß2-adrenoceptor agonists.	Astrazeneca
20462258	50	Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.	Glaxosmithkline
19317397	62	Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups.	Glaxosmithkline
9548813	53	The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.	Smithkline Beecham Pharmaceuticals
6330358	6	The 3,4-catechol derivative of propranolol, a minor dihydroxylated metabolite.	TBA
6148422	36	Synthesis and beta-adrenergic blocking activity of new aliphatic and alicyclic oxime ethers.	TBA
6134834	54	Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class.	TBA
6130154	68	Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function.	TBA
6130153	66	Ultra-short-acting beta-adrenergic receptor blocking agents. 1. (Aryloxy)propanolamines containing esters in the nitrogen substituent.	TBA
6120237	15	2-Benzodioxinylaminoethanols: a new class of beta-adrenergic blocking and antihypertensive agents.	TBA
6104730	47	Synthesis and beta-adrenergic blocking activity of new aliphatic oxime ethers.	TBA
11454468	35	Discovery and SAR of org 24598-a selective glycine uptake inhibitor.	Organon Research and Development Group
21486038	177	Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.	H. Lundbeck
22386241	46	Synthesis and pharmacological evaluation of carbamic acid 1-phenyl-3-(4-phenyl-piperazine-1-yl)-propyl ester derivatives as new analgesic agents.	Sk Biopharmaceuticals
22313227	78	Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype.	National Institute of Mental Health
24900353	6	Combination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity.	TBA
24900360	24	Synthesis and Cardiac Imaging of (18)F-Ligands Selective for ß1-Adrenoreceptors.	TBA
21726069	98	Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.	University of Namur
21207959	69	Syntheses of 2-amino and 2-halothiazole derivatives as high-affinity metabotropic glutamate receptor subtype 5 ligands and potential radioligands for in vivo imaging.	National Institute of Mental Health
20875743	90	Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity rela	Pfizer
20931963	112	Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.	Aska Pharmaceutical
20684563	176	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.	H. Lundbeck
20181479	177	Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles.	Merck Research Laboratories
19963380	38	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.	Hunter College and The Graduate Center of The City University of New York
19608416	29	Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6.	Astellas Pharma
19581100	162	Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.	Astellas Pharma
19232786	72	Discovery of novel acetanilide derivatives as potent and selective beta3-adrenergic receptor agonists.	Astellas Pharma
18651730	123	Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.	Astellas Pharma
16562853	22	Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.	Tom'S of Maine
18307290	97	Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.	Astellas Pharma
16451077	86	Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.	Pfizer
16198561	99	Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.	Novartis Institutes For Biomedical Research
16250647	71	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.	Universit£
15603933	28	Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist.	Fujisawa Pharmaceutical
12213075	70	Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).	Purdue University
11311069	64	(4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists.	Wyeth-Ayerst Research
11585444	295	From hit to lead. Analyzing structure-profile relationships.	Universities of Lille
7562902	114	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.	Smithkline Beecham Pharmaceuticals
7658429	31	(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431).	Abbott Laboratories
8254623	54	Syntheses of 2,5- and 2,6-difluoronorepinephrine, 2,5-difluoroepinephrine, and 2,6-difluorophenylephrine: effect of disubstitution with fluorine on adrenergic activity.	National Institute of Diabetes and Digestive and Kidney Diseases
8230093	34	Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.	Universit£
1313109	40	Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.	Universit£
1359141	47	Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines.	Merck Sharp and Dohme Research Laboratories
2319556	16	Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.	Berlex Laboratories
1976812	62	Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.	Berlex Laboratories
2845082	35	Syntheses and adrenergic activities of ring-fluorinated epinephrines.	National Institute of Diabetes
6126588	12	Use of (S)-(trifloxymethyl)oxirane in the synthesis of a chiral beta-adrenoceptor antagonist, (R)- and (S)-9-[[3-(tert-butylamino)-2-hydroxypropyl]oximino]fluorene.	TBA
15203136	39	(+/-)8-Amino-5,6,7,8-tetrahydroisoquinolines as novel antinociceptive agents.	Virginia Commonwealth University
	8	Synthesis and pharmacological characterization of A-80426: A putative novel antidepressant combining -2 antagonism with 5-HT uptake inhibition	TBA
21863888	9	Efficient conversion of a nonselective norepinephrin reuptake inhibitor into a dual muscarinic antagonist-ß2-agonist for the treatment of chronic obstructive pulmonary disease.	Pfizer
21783363	10	Synthesis and in vitro evaluation of derivatives of theß¿?-adrenergic receptor antagonist HX-CH 44.	University of Toronto
20036561	39	Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective beta(2)-adrenergic receptor agonists.	Medical University of Lublin
21353541	25	Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective humanß3 adrenergic receptor agonists.	Merck Research Laboratories
21277205	26	Discovery of substituted phenyl urea derivatives as novel long-actingß2-adrenoreceptor agonists.	RhôNe-Poulenc Rorer
20833036	221	Thienopyrimidines asß3-adrenoceptor agonists: hit-to-lead optimization.	4Sc
20812727	157	Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography.	National Institute of Mental Health
20813948	63	Spiroindolones, a potent compound class for the treatment of malaria.	Swiss Tropical and Public Health Institute
20655218	72	A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.	Novartis Institutes For Biomedical Research
20684592	83	Identification of potent and selective amidobipyridyl inhibitors of protein kinase D.	Novartis Institutes For Biomedical Research
20684591	87	Identification of orally available naphthyridine protein kinase D inhibitors.	Novartis Institutes For Biomedical Research
20620058	41	Smoothened antagonists for hair inhibition.	Pfizer
20591666	66	A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.	Università
20434333	111	A vHTS approach for the identification of beta-adrenoceptor ligands.	4Sc
20384344	42	Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.	Meiji Seika Kaisha
20096576	41	Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy.	Boehringer Ingelheim Pharma
19646882	72	Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.	University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School and The Informatics Institute of Umdnj
19643607	26	Studies towards topical selective beta2-adrenoceptor agonists with a long duration of action.	Boehringer Ingelheim Pharma
19875286	44	Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as beta2-adrenoceptor agonists.	Boehringer Ingelheim Pharma
19783143	65	Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.	Novartis Institutes For Biomedical Research
	38	Carboxyl-promoted enhancement of selectivity for the β3 adrenergic receptor. Negative charge of the sulfonic acid BMS-187413 introduces-β3 binding selectivity	TBA
	7	SYNTHESIS AND BIOLOGICAL EVALUATION OF A FLUORINATED ANALOG OF THE β-ADRENERGIC BLOCKING AGENT, METOPROLOL	TBA
	26	BMS-187257, a potent, selective, and novel heterocyclic β3 adrenergic receptor agonist	TBA
	3	Asymmetric synthesis of FR165914: A novel β3-adrenergic agonist with a benzocycloheptene structure	TBA
19492813	56	Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.	Glaxosmithkline
19366244	138	Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5.	Astellas Pharma
19362005	74	Synthesis and evaluation of novel phenoxypropanolamine derivatives containing acetanilides as potent and selective beta3-adrenergic receptor agonists.	Astellas Pharma
19131251	9	Preliminary evaluation of pharmacological properties of some xanthone derivatives.	Jagiellonian University Medical College
19081260	10	Substituted 1,2,3,4-tetrahydroquinolin-6-yloxypropanes as beta3-adrenergic receptor agonists: design, synthesis, biological evaluation and pharmacophore modeling.	Central Drug Research Institute
18752946	47	Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human beta(3)-adrenergic receptor agonists: Part IV.	Astellas Pharma
18701276	97	Highly functionalized 7-azaindoles as selective PPAR gamma modulators.	Merck Research Laboratories
18656910	2	Facile radiosynthesis of fluorine-18 labeled beta-blockers. Synthesis, radiolabeling, and ex vivo biodistribution of [18F]-(2S and 2R)-1-(1-fluoropropan-2-ylamino)-3-(m-tolyloxy)propan-2-ol.	Centre For Addiction and Mental Health
18640038	74	Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.	Amgen
18599160	4	Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol and its enantiomers. Part 1.	RzeszóW University of Technology
18553954	126	Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.	Astellas Pharma
17911024	37	Potent oxindole based human beta3 adrenergic receptor agonists.	Eli Lilly
17804228	44	Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.	Eli Lilly
17632003	55	Discovery of potent and orally bioavailable heterocycle-based beta3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity.	Pfizer
17571866	49	Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography.	National Institute of Mental Health
17533126	78	Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations.	Bristol-Myers Squibb Pharmaceutical Research Institute
17524641	69	3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.	Glaxosmithkline
17506540	52	Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor.	Medical University of Lublin
17303428	22	Novel chiral isoxazole derivatives: synthesis and pharmacological characterization at human beta-adrenergic receptor subtypes.	Università
16931005	21	Potent benzimidazolone based human beta(3)-adrenergic receptor agonists.	Eli Lilly
16392798	46	Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.	Columbia University College of Physicians and Surgeons
16361098	70	Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.	F. Hoffmann-La Roche
15686912	35	Tryptamine-based human beta3-adrenergic receptor agonists. Part 3: improved oral bioavailability via modification of the sulfonamide moiety.	Dainippon Pharmaceutical
15546708	35	Tryptamine-based human beta3-adrenergic receptor agonists. Part 2: SAR of the methylene derivatives.	Dainippon Pharmaceutical
15546707	60	Tryptamine-based human beta3-adrenergic receptor agonists. Part 1: SAR studies of the 7-position of the indole ring.	Dainippon Pharmaceutical
14643338	124	Binding of beta-carbolines at 5-HT(2) serotonin receptors.	Virginia Commonwealth University
12798332	35	Cyclic amine sulfonamides as linkers in the design and synthesis of novel human beta(3) adrenergic receptor agonists.	Wyeth Research
12657269	52	Novel and potent human and rat beta3-adrenergic receptor agonists containing substituted 3-indolylalkylamines.	Dainippon Pharmaceutical
12361399	17	Homoazanicotine: a structure-affinity study for nicotinic acetylcholine (nACh) receptor binding.	Universita Di Camerino
12270184	34	Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 2: arylethanolaminomethylpiperidines.	Wyeth Research
12270183	45	Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 1: aryloxypropanolaminomethylpiperidines.	Wyeth Research
11720857	37	4-Aminopiperidine ureas as potent selective agonists of the human beta(3)-adrenergic receptor.	Wyeth-Ayerst Research
11327605	27	New oxadiazolidinedione derivatives as potent and selective human beta3 agonists.	Wyeth-Ayerst Research
11277513	25	2,4-Thiazolidinediones as potent and selective human beta3 agonists.	Wyeth-Ayerst Research
11212115	72	Human beta3 adrenergic receptor agonists containing cyanoguanidine and nitroethylenediamine moieties.	Merck Research Laboratories
32227883	40	Isolation and Synthesis of Veranamine, an Antidepressant Lead from the Marine Sponge	University of Mississippi
31753798	49	Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent ?	Shenyang Pharmaceutical University
11055339	59	Tetrahydroisoquinoline derivatives containing a benzenesulfonamide moiety as potent, selective human beta3 adrenergic receptor agonists.	Merck Research Laboratories
11052788	33	Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide.	Merck Research Laboratories
10999482	52	Human beta3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides.	Merck Research Laboratories
10987429	69	Potent, selective 3-pyridylethanolamine beta3 adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophore.	Merck Research Laboratories
10915043	69	Substituted oxazole benzenesulfonamides as potent human beta3 adrenergic receptor agonists.	Merck Research Laboratories
10888325	90	Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents.	Merck Research Laboratories
10888324	48	Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist.	Merck Research Laboratories
10780918	27	Syntheses of (R)- and (S)-2- and 6-fluoronorepinephrine and (R)- and (S)-2- and 6-fluoroepinephrine: effect of stereochemistry on fluorine-induced adrenergic selectivities.	National Institute of Diabetes and Digestive and Kidney Diseases
10743949	76	(1,4-Benzothiazinyloxy)alkylpiperazine derivatives as potential antihypertensive agents.	Università
31625751	12	Synthesis, Purification, and Selective ?	Shandong University
32342685	325	Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D	National Institute of Neurological Disorders and Stroke
31151791	35	Development of covalent antagonists for ?1- and ?2-adrenergic receptors.	Friedrich-Alexander Universit£T Erlangen-N£Rnberg
31042379	96	Hybridization of ?-Adrenergic Agonists and Antagonists Confers G Protein Bias.	Friedrich-Alexander University Erlangen-N£Rnberg (Fau)
10406657	91	Potent, elective human beta3 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophore.	Merck Research Laboratories
30875219	254	Defining Structure-Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D	University of North Carolina At Chapel Hill
10360736	2	S1319: a novel beta2-andrenoceptor agonist from a marine sponge Dysidea sp.	Kirin Brewery
10340609	15	L-770,644: a potent and selective human beta3 adrenergic receptor agonist with improved oral bioavailability.	Merck Research Laboratories
10201842	69	Human beta3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides.	Merck Research Laboratories
10201841	47	Human beta3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides.	Merck Research Laboratories
31298548	112	Probing the Existence of a Metastable Binding Site at the ?	University of Copenhagen
9876110	58	7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602).	Centro De InvestigacióN Grupo Ferrer
9873681	65	3-Pyridylethanolamines: potent and selective human beta 3 adrenergic receptor agonists.	Merck Research Laboratories
9873496	80	3-Pyridyloxypropanolamine agonists of the beta 3 adrenergic receptor with improved pharmacokinetic properties.	Merck Research Laboratories
31185168	144	Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor.	Rti International
9871717	72	Discovery of L-755,507: a subnanomolar human beta 3 adrenergic receptor agonist.	Merck Research Laboratories
9871716	94	Potent, selective benzenesulfonamide agonists of the human beta 3 adrenergic receptor.	Merck Research Laboratories
30392952	49	Design, synthesis and biological evaluation of 5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one derivatives as potent ?	Shenyang Pharmaceutical University
9379432	36	Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist for the symptomatic treatment of benign pr	Abbott Laboratories
31613617	195	Benzyl Phenylsemicarbazides: A Chemistry-Driven Approach Leading to G Protein-Biased Dopamine D	Friedrich-Alexander-Universit£T Erlangen-N£Rnberg
31620230	283	3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT	University of Minnesota Twin Cities
26590100	42	Discovery of benzamides as potent human ?3 adrenergic receptor agonists.	Merck And
26565745	165	Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.	Janssen Pharmaceutica
31223445	4	Computer-Aided Selective Optimization of Side Activities of Talinolol.	Goethe-University of Frankfurt
8093626	13	o-Chlorobenzenesulfonamidic derivatives of (aryloxy)propanolamines as beta-blocking/diuretic agents.	Università
7910217	36	The [(methyloxy)imino]methyl moiety as a bioisoster of aryl. A novel class of completely aliphatic beta-adrenergic receptor antagonists.	Universitá
21170122	84	Comparative 3D QSAR study on ?(1)-, ?(2)-, and ?(3)-adrenoceptor agonists.	National Institute of Pharmaceutical Education and Research
21075638	105	Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists.	Drug Discovery Laboratory
17560786	48	Synthesis and evaluation of potent and selective beta3 adrenergic receptor agonists containing heterobiaryl carboxylic acids.	Glaxosmithkline
17129726	121	3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors.	Glaxosmithkline
10377236	15	2-Amino-4-benzyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridines: novel selective beta3-adrenoceptor agonists.	University of Tennessee
8809159	26	Iodinated analogs of trimetoquinol as highly potent and selective beta 2-adrenoceptor ligands.	University of Tennessee-Memphis
29751236	46	Synthesis and biological evaluation of ?	Shenyang Pharmaceutical University
29574204	54	Design and synthesis of aryloxypropanolamine as ?	East China Normal University
2892936	21	Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.	Warner-Lambert
2875184	57	(5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.	TBA
29656199	148	Investigating isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties.	University of Texas At Austin
29425815	76	Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT	Jagiellonian University Medical College
2563296	38	A new series of tricyclic (aryloximino)propanolamines displaying very high selective beta 2-blocking properties.	Université
29851481	122	Discovery of ?-Adrenergic Receptors Blocker-Carbonic Anhydrase Inhibitor Hybrids for Multitargeted Antiglaucoma Therapy.	University of Florence
29706529	22	Design, synthesis and cardiovascular evaluation of some aminoisopropanoloxy derivatives of xanthone.	Jagiellonian University Medical College
29631962	252	Identification and biological evaluation of thiazole-based inverse agonists of ROR?t.	Phenex Pharmaceuticals
28355078	34	Discovery of Novel Indazole Derivatives as Orally Available?	Asahi Kasei Pharma
29589445	154	1-[3-(4-Butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1) as a Model for the Rational Design of a Novel Class of Brain Penetrant Ligands with High Affinity and Selectivity for Dopamine D	Universit£
1672155	14	Effect of fluorine substitution on the adrenergic properties of 3-(tert-butylamino)-1-(3,4-dihydroxyphenoxy)-2-propanol.	National Institute of Diabetes
1652023	179	Synthesis and dopaminergic activity of 3-substituted 1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyrans: characterization of an auxiliary binding region in the D1 receptor.	Abbott Laboratories
1354264	19	Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent.	American Cyanamid
1347318	52	Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.	Berlex Laboratories
	7	Synthesis and pharmacological evaluation of 4-[2- hydroxy-3-(4-phenyl-piperazin-1-yl)-propoxy]-4- azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione	The Medical University of Warsaw
19337725	43	Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo.	Case Western Reserve University
16915381	31	WAY-100635 is a potent dopamine D4 receptor agonist.	Purdue University
16352709	44	Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.	Mcgill University
15831442	46	Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke.	Taisho Pharmaceutical
15131245	86	SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.	Sanofi-Synthelabo Recherche
14730417	62	Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.	UniversitÄT WÜRzburg
12784105	53	Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.	Case Western Reserve University
12761331	97	3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.	Case Western Reserve University
12649361	779	L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists.	Case Western Reserve University
12431845	84	Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.	Eli Lilly
12388666	301	Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.	Institut De Recherches Servier
12192085	52	Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.	Case Western Reserve University
12110997	380	In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs.	WestfÄLische Wilhelms-UniversitÄ
11750183	29	Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders.	Novartis Pharma
11750180	139	Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.	Eli Lilly
11512051	80	The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor.	Case Western Reserve University
11438309	51	The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.	Janssen Research Foundation
11356907	15	Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.	Institut De Recherches Servier
11082457	63	S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.	Centre De Recherches De Croissy
11082453	77	ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse.	Abbott Laboratories
9454810	72	SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.	Sanofi Recherche
9225287	174	RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist.	Roche Bioscience
9144661	24	BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats.	Smithkline Beecham Pharmaceuticals
8935801	586	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.	Janssen Research Foundation
8788493	64	Novel discriminatory ligands for 5-HT2B receptors.	Smithkline Beecham Pharmaceuticals
8730737	23	Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety.	Smithkline Beecham Pharmaceuticals
8584042	40	BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex.	Boehringer Ingelheim Italia
8564196	35	Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo.	Syntex Discovery Research
8012715	38	GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor.	Glaxo Group Research
7921604	16	The effects of SB 204070, a highly potent and selective 5-HT4 receptor antagonist, on guinea-pig distal colon.	Smithkline Beecham Pharmaceuticals
7915318	120	Biochemical and pharmacological characterization of high-affinity trimetoquinol analogs on guinea pig and human beta adrenergic receptor subtypes: evidence for partial agonism.	Ohio State University
2530094	94	The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.	Novo Industri
1982626	30	Neurochemical profile of eltoprazine.	Duphar
1968985	56	Characteristics of 125I-iodocyanopindolol binding to beta-adrenergic and serotonin-1B receptors of rat brain: selectivity of beta-adrenergic agents.	Niigata College of Pharmacy
1661335	95	Receptor binding profiles of amiloride analogues provide no evidence for a link between receptors and the Na+/H+ exchanger, but indicate a common structure on receptor proteins.	Center For Bio-Pharmaceutical Sciences
15655528	75	The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.	University of Nottingham